. Author manuscript; available in PMC: 2020 Jun 2.

Published in final edited form as: J Neurosurg Pediatr. 2018 Dec 7;23(3):333–342. doi: 10.3171/2018.9.PEDS17225

TABLE 2.

Treatments and their timing before IL13-PE infusion

Pt No.	Dx to End of RT (wks)	End of RT to End of Chemo (wks)	End of Chemo to IL13-PE Infusion (wks)	1st IL13-PE Infusion to Death (wks)	Dx to Death (wks)	Chemo Regimens^*
1	7.9	18.6	8.0	22.0	56.4	Vandetanib
2	8.0	0.9	22.9	4.7	36.3	Vorinostat
3	8.0	32.9	4.1	35.61^†	80.9	a) Cetuximab & irinotecan; b) MK2206
4	5.4	69.1	5.0	9.3	88.9	a) PEG irinotecan; b) VOIT; c) avastin & etoposide
5	6.3	38.3	4.0	24.31^†	72.9	a) Temozolomide, vorinostat, avastin; b) temsirolimus

Chemo = chemotherapy; Dx = diagnosis; PEG = polyethylene glycol; pt = patient; RT = radiation therapy; VOIT = vincristine, oral irinotecan, and temozolomide.

^†

Patients received second IL13-PE infusion 4 weeks after first IL13-PE infusion.

Letters (a, b, c) indicate sequence of chemotherapeutic regimens.